Skip to main content
CLOSE

Charities

Close

Corporates and Business Services

Close

Employment and Immigration

Close

Fraud and Investigations

Close

Individuals

Close

Litigation

Close

Pensions

Close

Planning, Infrastructure and Regeneration

Close

Public Law

Close

Real Estate

Close

Restructuring and Insolvency

Close
Home / News and Insights / News / Bircham Dyson Bell advises ImmuPharma PLC on its £10 million fundraising

Bircham Dyson Bell acted for ImmuPharma PLC, the AIM-listed specialist drug discovery and development company, in relation to its fundraising, which raised £10 million by way of a share subscription and placing with new and existing shareholders.

The transaction was led by corporate partner Philip Lamb and senior associate Tessa Trevelyan Thomas.

Philip Lamb comments:

‘We are delighted by the successful outcome of this fundraising at an exciting stage of the company’s development, and to be continuing our long-standing relationship with the company dating back to before it floated in 2006.’

Related Articles